Neuronetics, Inc. (STIM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.88+5.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Neuronetics aims for $160M-$166M revenue in 2026, showing growth potential. The company targets a stable gross margin of 47%-49%. Cost cuts with a 5% workforce reduction improve efficiency. New partnerships and leadership changes support future progress.
The company is still loss-making with negative free cash flow of $13M-$17M in 2026. Revenue growth is uncertain given only $34.45M in Q1. Management changes and workforce cuts may signal instability. Profit margins and cash flow targets are not yet met.
The market expects about 13% revenue growth and values the stock cheaply versus peers. Our fair value near $9.57 implies some optimism but the recent 29% drawdown reflects risk. We see uncertainty in reaching profitability and growth targets.
Breaks if: Workforce reduction delayed or expanded beyond 5%
Implement workforce reduction of up to 5% of employees to optimize cost structure and reduce operating expenses.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently navigating a volatile management phase while aiming for revenue growth and cost optimization.
The market appears to have priced in a low expectations gap, suggesting that investors are cautious about STIM's future performance. Compared to peers, STIM is seen as relatively cheap, but this valuation comes with a low confidence in the underlying model.
Management is on track to achieve its revenue and gross margin goals, which could support a more stable financial performance. However, the company remains loss-making, and risks from the broader economic environment could impact its trajectory.
The long-term thesis hinges on STIM's ability to raise guidance in upcoming quarters and the performance of key sector players. Additionally, macroeconomic indicators, like the jobs report, could significantly affect investor sentiment and the company's performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Revenue guidance of $160M-$166M for 2026 reinforces this improvement. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 3 quarters. Operating expenses decreased from $25.8 million in 2025-Q2 to $22.7 million in 2026-Q2, a 12% reduction, reflecting progress on workforce reduction and cost optimization. Management expects completion of workforce reduction by mid-2026, indicating delivering on cost structure optimization.
“Workforce reduction impacting up to 5% of employees, restructuring charges of $0.2 million expected in Q2 2026.”
“Operating expenses decreased by 6% compared to prior year, reflecting cost savings initiatives.”
Breaks if: gross margin falls below 47% in FY26
Sustain gross margin in the range of 47% to 50% throughout fiscal year 2026.
Stated as a priority in 3 of last 3 quarters. Gross margin improved from 46.6% in 2025-Q2 to 51.1% in 2026-Q2, exceeding the 47%-50% guidance range. Management has consistently maintained this margin target, and the trajectory shows delivering on margin improvement.
“Gross margin between 48% and 50%.”
“Gross margin between 47% and 49%.”
“Gross Margin Between 47% and 49%.”
Breaks if: annual revenue falls below $147M in FY26
Over the next 1 to 3 years, STIM's outlook will depend on its execution and external economic factors. Not investment advice.